Abstract
The present industry update covers the period 15 August–15 September 2012, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. The internationally rougher financial climate especially in the EU zone is also affecting investments in the medical drug and device industry including drug-delivery technology providers. Maybe not just coincidentally, one can observe a strive for public funding such as with the University of Liverpool (Liverpool, UK) and Penn State College (PA, USA) and precompetitive public–private partnerships as the recently announced by Capsugel. The first bioabsobable drug-eluting stent from Abbott was approved while successful clinical trials on sustained-release technologies for diabetes (University of Cambridge) and cancer treatment (Hospital Amaral Carvalho, Brazil) were reported.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
